Progress in rare central nervous system tumors.

Area of Science:

• Neuro-oncology
• Molecular Pathology
• Clinical Trial Design

Background:

• Primary central nervous system (CNS) tumors are rare, with specific types affecting fewer than 1000 patients annually.
• These rare CNS tumors disproportionately affect children and young adults, with limited clinical trial participation in older adults.
• Advances in molecular techniques are driving reclassification and identifying actionable molecular alterations in rare CNS tumors.

Purpose of the Study:

• To review recent progress in molecular understanding of rare CNS tumors.
• To discuss current and emerging therapeutic options, including clinical trials and tumor-agnostic approvals.
• To highlight the challenges and future research directions for rare CNS tumors.

Main Methods:

• Review of recent literature on molecular characterization of rare CNS tumors.
• Analysis of select clinical trials investigating targeted therapies (e.g., temozolomide, lapatinib, vemurafenib).
• Examination of tumor-agnostic drug approvals (e.g., pembrolizumab, larotrectinib) and their relevance.

Main Results:

• Progress in molecular understanding has identified actionable targets in rare CNS tumors.
• Specific clinical trials and tumor-agnostic therapies show promise for certain rare CNS tumor subtypes.
• Challenges remain in trial design, biomarker persistence, and understanding resistance mechanisms.

Conclusions:

• Rare CNS tumors require dedicated clinical trials with correlative science components for all age groups.
• Further research is needed to address target relevance, biomarker dynamics, blood-brain barrier penetration, and resistance mechanisms.
• Molecular insights are paving the way for more personalized therapeutic strategies in rare CNS oncology.